Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

30 mars 2023 08h00 HE | Source: Avalyn Pharma Inc.

Avalyn Pharma Reports Results of Phase 1 Study of AP02 in Healthy Volunteers and Participants with Idiopathic Pulmonary Fibrosis

Seattle, March 30, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases, today...
23 mars 2023 13h23 HE | Source: Avalyn Pharma Inc.

Avalyn Pharma Publishes Phase 1b ATLAS Results Demonstrating Stabilization of Lung Function at 24 and 48 Weeks with AP01 and Favorable Safety Profile

SEATTLE , March 23, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on the development of targeted therapies for life-threatening pulmonary diseases,...
28 nov. 2022 12h00 HE | Source: Avalyn Pharma Inc.

Avalyn Pharma Invited to Participate in the Annual Evercore ISI HealthCONx Conference

SEATTLE , Nov. 28, 2022 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases,...